Trump Signs Marijuana Reclassification Order: Major Step to Ease Research – But Critics Say It’s Not Enough for Full Legalization
In a surprise pre-holiday move, President Trump signed an executive order reclassifying marijuana from Schedule I to Schedule III under the Controlled Substances Act, easing barriers for medical research and potentially paving the way for broader reforms. Announced December 20, 2025, the directive aims to “unlock science” on cannabis benefits, fulfilling a campaign nod to states’ rights.
Supporters hail it as a breakthrough: Schedule III status recognizes marijuana’s medical potential, like pain relief for veterans, while maintaining federal controls. Trump’s team touts it as pro-business, projecting billions in research investments and tax revenue from regulated markets. “This is common sense for America,” Trump tweeted.
But critics blast it as half-measure. Advocacy groups like NORML argue it falls short of full legalization, leaving criminal penalties intact and ignoring recreational use. “It’s a baby step when we need a leap,” said Sen. Cory Booker (D-NJ), pushing for descheduling. Bipartisan voices, including some Republicans, echo demands for banking reforms to aid legal cannabis industries in 24 states.
The order follows Trump’s 2024 pledges but sidesteps thorny issues like pardons for nonviolent offenders. Public opinion favors change—68% support legalization per Pew—but conservatives worry about societal impacts.
As 2026 approaches, this could boost Trump’s image among moderates amid approval dips. Yet without bolder action, discontent simmers. Will it evolve into full reform? Watch Congress.
